Abstract
This study determined the effect of Ad-E1A gene therapy in vivo. TC71 cells (2×106) injected subcutaneously into nude mice resulted in tumor development (1–3 mm) 6 days later. Animals were then treated with Ad-E1A or Ad-β-gal (5×109 plaque-forming units) by intratumoral injection twice weekly for 2 weeks. Animals received 8 mg/kg VP-16 given by intraperitoneal injection daily for 5 days following the first week of treatment with Ad-E1A or Ad-β-gal. Control animals received no therapy or VP-16 only after tumor cells were injected. When tumors exceeded 2×2 cm, the mice were sacrificed and the tumors underwent histologic and immunohistochemical analysis. Tumors from mice treated with Ad-E1A plus VP-16 were 9.6-fold smaller than those treated with VP-16 alone and 6.3-fold smaller than those treated with Ad-E1A alone. HER2/neu p185 protein expression decreased in all tumors that received Ad-E1A therapy. TUNEL fluorescence staining revealed more apoptosis in the tumors from animals treated with Ad-E1A plus VP-16 than in those from animals treated with Ad-E1A alone, Ad-β-gal plus VP-16, or VP-16 alone. These data demonstrated that Ad-E1A gene therapy down-regulated HER2/neu expression, increased tumor cell apoptosis induced by VP-16, and enhanced tumor cell sensitivity to VP-16. Ad-E1A may have potential in the treatment of relapsed drug-resistant Ewing's sarcoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dorfman HD, Czerniak B . Bone cancers Cancer 1995 75: 203–210
Horowitz ME, Malawer MM, Woo SY et al. Ewing's sarcoma family of tumor: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors In: Pizzo PA, Poplack DG, eds Principles and Practice of Pediatric Oncology Philadelphia: Lippincott-Raven Publishers 1997 831–863
Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989 44: 707–712
Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 1990 50: 4087–4091
Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erB-2 correlates with survival in osteosarcoma J Clin Oncol 1999 17: 2781–2791
Onde M, Matsuda S, Higuki S et al. Erb-2 expression is correlated with poor prognosis for patients with osteosarcoma Cancer 1995 7: 71–78
Chen H, Hung MC . Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene J Biol Chem 1997 272: 6101–6104
Yu D, Hamada J, Zhang H et al. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products Oncogene 1992 7: 2263–2270
Yu DH, Scorsone K, Hung MC . Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene Mol Cell Biol 1991 11: 1745–1750
Yu D, Suen T, Yan D et al. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products Proc Natl Acad Sci USA 1990 87: 4499–4503
Zhou Z, Jia S-F, Hung MC et al. E1A sensitizes Her2/neu overexpressing Ewing's sarcoma cells to topoisomerase II–targeting anticancer drugs Cancer Res 2001 61: 3394–3398
Hung MC, Wang SC, Hortobagyi GN . Targeting Her-2/neu overexpressing cancer cells with transcriptional repressor genes delivered by liposome In: Hung L, Hung MC, Wagner E, eds Cancer Gene Therapy Using Cationic Liposome: Preclinic and Clinic Studies San Diego: Academic Press 1999 357–377
Graham FL, Prevec L . Manipulation of adenovirus vector. Gene transfer and expression protocols In: Murray EJ, ed Methods in Molecular Biology: Gene Transfer and Expression. Protocols, Vol 7 Clifton, NJ: The Humana Press 1991 7: 109–128
Jia S-F, Zhou R-R, Kleinerman ES . Nude mouse lung metastases of osteosarcoma and Ewing's sarcoma for evaluating new therapeutic strategies In: Driscoll B, ed Lung Cancer: Methods and Protocols Totowa, NJ: The Humana Press In press
Yu D, Wolf JK, Scanlon M et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A Cancer Res 1993 53: 891–898
Zhang Y, Yu D, Xia W et al. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model Oncogene 1995 10: 1947–1954
Chang JY, Xia W, Shao R et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer Oncogene 1997 14: 561–568
Chang JY, Xia W, Shao R et al. Inhibition of intratracheal lung cancer development by systemic delivery of E1A Oncogene 1996 13: 1405–1412
Frisch SM . Antioncogenic effect of adenovirus E1A in human tumor cells Proc Natl Acad Sci USA 1991 88: 9077–9081
Frisch SM, Dolter KE . Adenovirus E1a–mediated tumor suppression by a c-erbB-2/neu-independent mechanism Cancer Res 1995 55: 5551–5555
Moran E, Mathews M . Multiple functional domains in the adenovirus E1A gene Cell 1987 48: 177–178
Frisch S, Reich R, Collier I et al. Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells Oncogene 1990 5: 75–83
Frisch SM . Antioncogenic effect of adenovirus E1A in human tumor cells Proc Natl Acad Sci USA 1991 88: 9077–9081
Pozzatti R, McCormick M, Thompson MA et al. The E1a gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells Mol Cell Biol 1988 8: 2984–2988
Lowe SW, Ruley H, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993 74: 957–967
Rao L, Debbas M, Sabbatini P et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins Proc Natl Acad Sci USA 1992 89: 7742–7746
Teodoro JG, Shore GC, Branton PE . Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms Oncogene 1995 11: 467–474
Putzer B, Stiewe T, Parssanedjad K et al. E1A is sufficient by itself to induce apoptosis independent of P53 and other adenoviral gene products Cell Death Differ 2000 7: 177–188
Ueno NT, Bartholomeusz C, Herrmann JL et al. E1A-mediated paclitaxel sensitization in Her2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway Clin Cancer Res 2000 16: 250–259
Hortobagyi GN, Hung MC, Lopez-Berestein G . A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer Hum Gene Ther 1998 9: 1775–1798
Weiner DB, Nordberg J, Robinson R et al. Expression of the neu gene–encoded protein (P185neu) in human nonsmall cell carcinomas of the lung Cancer Res 1990 50: 421–425
Zhou Z, Zhou RR, Hung MC et al. E1A down-regulated VEGF and MMP-9 Expression in TC-71 Ewing's sarcoma cells Proceedings of the American Association for Cancer Research, New Orleans, LA 2001 42: 410 Ab# 2210
Toi M, Bando H, Kuroi K . The predictive value of angiogenesis for adjuvant therapy in breast cancer Breast Cancer 2000 7: 311–314
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, RR., Jia, SF., Zhou, Z. et al. Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16. Cancer Gene Ther 9, 407–413 (2002). https://doi.org/10.1038/sj.cgt.7700449
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700449